Guidelines for palliative surgery of cholangiocarcinoma

Autor Witzigmann, H., Lang, H., Lauer, H.
Vydáno 2008

An unusual cause and treatment for ascites after liver transplantation

Autor Feisthammel, J, Troltzsch, M, Witzigmann, H, Mossner, J, Caca, K
Vydáno 2006

Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

Autor Halm, U, Schumann, T, Schiefke, I, Witzigmann, H, Mössner, J, Keim, V
Vydáno 2000

INK4a-ARF alterations in liver cell adenoma

Autor Tannapfel, A, Busse, C, Geiβler, F, Witzigmann, H, Hauss, J, Wittekind, C
Vydáno 2002

INK4a-ARF alterations in liver cell adenoma

Autor Tannapfel, A, Busse, C, Geiβler, F, Witzigmann, H, Hauss, J, Wittekind, C
Vydáno 2002

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

Autor Tannapfel, A, Sommerer, F, Benicke, M, Katalinic, A, Uhlmann, D, Witzigmann, H, Hauss, J, Wittekind, C
Vydáno 2003

Heparanase is a prognostic indicator for postoperative survival in pancreatic carcinoma

Autor Rohloff, J, Zinke, J, Schoppmeyer, K, Tannapfel, A, Witzigmann, H, Mössner, J, Wittekind, C, Caca, K
Vydáno 2002

Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma

Autor Rohloff, J, Zinke, J, Schoppmeyer, K, Tannapfel, A, Witzigmann, H, Mössner, J, Wittekind, C, Caca, K
Vydáno 2002